Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma

American Journal of Hematology

Volumn 87, Issue 8, 2012, Pages 766-769

  Bi, Xiaofeng ^a,b   Zheng, Tongzhang ^b   Lan, Qing ^c   Xu, Zhijian ^a   Chen, Yingtai ^a   Zhu, Gongjian ^d   Foss, Francine ^e   Kim, Christopher ^b   Dai, Min ^a   Zhao, Ping ^a   Holford, Theodore ^b   Leaderer, Brian ^b   Boyle, Peter ^f   Deng, Qian ^g   Chanock, Stephen J ^c   Rothman, Nathaniel ^c   Zhang, Yawei ^b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b YALE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d GANSU PROVINCIAL HOSPITAL   (China)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^g SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10 RECEPTOR ALPHA; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD TRANSFUSION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PRIORITY JOURNAL; STATISTICAL ANALYSIS; T CELL LYMPHOMA; TH1 CELL; TH2 CELL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; CONNECTICUT; FEMALE; HUMANS; INTERLEUKIN-10 RECEPTOR ALPHA SUBUNIT; LYMPHOMA, B-CELL; MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863995395     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23244     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Schulz TF. Cancer and viral infections in immunocompromised individuals. Int J Cancer 2009; 125: 1755-1763.
3. Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: A review of the epidemiologic literature. Int J Cancer 2007; 120( Suppl 12): 1-39.
4. Brunson ME, Alexander JW. Mechanisms of transfusion-induced immunosuppression. Transfusion 1990; 30: 651-658.
5. Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med 1994; 118: 371-379.
6. Triulzi DJ, Heal JM, Blumberg N. Transfusion-induced immunomodulation and its clinical consequences. In: Nance SJ, editor. Transfusion Medicine in the 1990′s. Arlington, VA: American Association of Blood Banks; 1990. pp 1-33.
7. Klein HG. Immunomodulatory aspects of transfusion: A once and future risk? Anesthesiology 1999; 91: 861-865.
8. Castillo JJ, Dalia S, Pascual SK. Association between red blood cell transfusions and development of non-Hodgkin lymphoma: A meta-analysis of observational studies. Blood 2010; 116: 2897-2907.
9. Chow EJ, Holly EA. Blood transfusions and non-Hodgkin's lymphoma. Epidemiol Rev 2002; 24: 269-279.
10. Cerhan JR. New epidemiologic leads in the etiology of non-Hodgkin lymphoma in the elderly: The role of blood transfusion and diet. Biomed Pharmacother 1997; 51: 200-207.
11. Zhang Y, Holford TR, Leaderer B, et al. Blood transfusion and risk of non-Hodgkin's lymphoma in Connecticut women. Am J Epidemiol 2004; 160: 325-330.
12. Chiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 2003; 4: 161-168.
13. Mori T, Takada R, Watanabe R, et al. T-helper (Th)1/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma. Cancer Immunol Immunother 2001; 50: 566-568.
14. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006; 107: 4101-4108.
15. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncol 2006; 7: 27-38.
16. Liese AM, Siddiqi MQ, Siegel JH, et al. Augmented TNF-alpha and IL-10 production by primed human monocytes following interaction with oxidatively modified autologous erythrocytes. J Leukoc Biol 2001; 70: 289-296.
17. Chen Y, Zheng T, Lan Q, et al. Cytokine polymorphisms in Th1/Th2 pathway, body mass index, and risk of non-Hodgkin lymphoma. Blood 2011;117:585-590.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289-300.
19. Khatri VP, Caligiuri MA. A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunol Immunother 1998; 46: 239-244.
20. Aggarwal BB. Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 2003; 3: 745-756.
21. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13: 135-141.
22. Korner H, Cretney E, Wilhelm P, et al. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J Exp Med 2000; 191: 89-96.
23. Batten M, Fletcher C, Ng LG, et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004; 172: 812-822.
24. Czarneski J, Lin YC, Chong S, et al. Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma. Leukemia 2004; 18: 597-606.
25. Hod EA, Zhang N, Sokol SA, et al. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood 2010; 115: 4284-4292.
26. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: Fact or fiction? Blood 2001; 97: 1180-1195.
27. Spencer SD, Di Marco F, Hooley J, et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 1998; 187: 571-578.
28. Kotenko SV, Krause CD, Izotova LS, et al. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J 1997; 16: 5894-5903.
29. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
30. Sabat R, Grutz G, Warszawska K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010; 21: 331-344.
31. El-Far M, Fouda M, Yahya R, El-Baz H. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J Physiol Biochem 2004; 60: 253-258.
32. Pandey P, Chaudhary R, Aggarwal A, et al. Transfusion-associated immunomodulation: Quantitative changes in cytokines as a measure of immune responsiveness after one time blood transfusion in neurosurgery patients. Asian J Transfus Sci 2010; 4: 78-85.
33. Fernberg P, Chang ET, Duvefelt K, et al. Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control 2010; 21: 759-769.
34. Bel Hadj Jrad B, Chatti A, Laatiri A, et al. Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin's lymphomas. Eur J Haematol 2007; 78: 117-122.
35. Cerhan JR, Liu-Mares W, Fredericksen ZS, et al. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 3161-3169.
36. Wang SS, Cerhan JR, Hartge P, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 2006; 66: 9771-9780.
37. Hajeer AH, Hutchinson IV. TNF-alpha gene polymorphism: Clinical and biological implications. Microsc Res Tech 2000; 50: 216-228.
38. Karin M, Greten FR. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
39. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: Mechanisms, consequences, and therapeutic implications. Blood 2007; 109: 2700-2707.
40. Gill RM, Lee TH, Utter GH, et al. The TNF (-308A) polymorphism is associated with microchimerism in transfused trauma patients. Blood 2008; 111: 3880-3883.
41. Milasiene V, Stratilatovas E, Characiejus D, et al. TGF-beta1 and TNF-alpha after red blood cell transfusion in colorectal cancer patients. Exp Oncol 2007; 29: 67-70.